Tigecycline Dosage

This dosage information may not include all the information needed to use Tigecycline safely and effectively. See additional information for Tigecycline.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Intraabdominal Infection

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 5 to 14 days, depending on the nature and severity of the infection

Approved indications:
-For treatment of complicated intraabdominal infections (due to susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K pneumoniae, Enterococcus faecalis [vancomycin-susceptible isolates], Staphylococcus aureus [methicillin-susceptible and -resistant isolates], Streptococcus anginosus group [includes S anginosus, S intermedius, and S constellatus], Bacteroides fragilis, B thetaiotaomicron, B uniformis, B vulgatus, Clostridium perfringens, and Peptostreptococcus micros)
-For treatment of complicated skin and skin structure infections (due to susceptible isolates of E coli, E faecalis [vancomycin-susceptible isolates], S aureus [methicillin-susceptible and -resistant isolates], S agalactiae, S anginosus group [includes S anginosus, S intermedius, and S constellatus], S pyogenes, E cloacae, K pneumoniae, and B fragilis)

Usual Adult Dose for Skin or Soft Tissue Infection

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 5 to 14 days, depending on the nature and severity of the infection

Approved indications:
-For treatment of complicated intraabdominal infections (due to susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K pneumoniae, Enterococcus faecalis [vancomycin-susceptible isolates], Staphylococcus aureus [methicillin-susceptible and -resistant isolates], Streptococcus anginosus group [includes S anginosus, S intermedius, and S constellatus], Bacteroides fragilis, B thetaiotaomicron, B uniformis, B vulgatus, Clostridium perfringens, and Peptostreptococcus micros)
-For treatment of complicated skin and skin structure infections (due to susceptible isolates of E coli, E faecalis [vancomycin-susceptible isolates], S aureus [methicillin-susceptible and -resistant isolates], S agalactiae, S anginosus group [includes S anginosus, S intermedius, and S constellatus], S pyogenes, E cloacae, K pneumoniae, and B fragilis)

Usual Adult Dose for Skin and Structure Infection

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 5 to 14 days, depending on the nature and severity of the infection

Approved indications:
-For treatment of complicated intraabdominal infections (due to susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K pneumoniae, Enterococcus faecalis [vancomycin-susceptible isolates], Staphylococcus aureus [methicillin-susceptible and -resistant isolates], Streptococcus anginosus group [includes S anginosus, S intermedius, and S constellatus], Bacteroides fragilis, B thetaiotaomicron, B uniformis, B vulgatus, Clostridium perfringens, and Peptostreptococcus micros)
-For treatment of complicated skin and skin structure infections (due to susceptible isolates of E coli, E faecalis [vancomycin-susceptible isolates], S aureus [methicillin-susceptible and -resistant isolates], S agalactiae, S anginosus group [includes S anginosus, S intermedius, and S constellatus], S pyogenes, E cloacae, K pneumoniae, and B fragilis)

Usual Adult Dose for Pneumonia

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 7 to 14 days, depending on the nature and severity of the infection

Approved indication: For the treatment of community-acquired bacterial pneumonia (due to susceptible isolates of S pneumoniae [penicillin-susceptible isolates], including cases with concurrent bacteremia, Haemophilus influenzae [beta-lactamase negative isolates], and Legionella pneumophila)

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A and B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): 100 mg IV initial dose, followed by 25 mg IV every 12 hours; caution recommended

Precautions

Consult WARNINGS section for dosing related precautions.

Safety and efficacy have not been established in patients younger than 18 years. Due to effects on tooth development, tigecycline is not recommended in patients less than 8 years of age.

Dialysis

Hemodialysis: No adjustment recommended.
Peritoneal dialysis: Data not available

Other Comments

Administration advice:
-IV infusions should be administered over 30 to 60 minutes through a dedicated line or through a Y-site.
-If same IV line used for sequential infusion of several drugs, line should be flushed before and after tigecycline infusion; the manufacturer's product information should be consulted.

Storage requirements:
-Prior to reconstitution: Should be stored at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit); excursions permitted to 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit)
-After reconstitution: Tigecycline may be stored at room temperature (not to exceed 25 degrees Celsius [77 degrees Fahrenheit]) for up to 24 hours (up to 6 hours in the vial and the remaining time in the IV bag); if storage conditions exceed 25 degrees Celsius (77 degrees Fahrenheit), tigecycline should be used immediately. Alternatively, tigecycline mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) for up to 48 hours after immediate transfer of reconstituted solution into the IV bag.

Reconstitution/preparation techniques: The manufacturer's product information should be consulted.

IV compatibility:
-Compatible IV solutions: 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, Lactated Ringer's Injection, USP
-Compatible drugs/diluents (when used with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP): Amikacin, dobutamine, dopamine hydrochloride (HCl), gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin-tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, tobramycin
-Incompatible drugs: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole

General:
-Each vial contains 100 mg lactose monohydrate.

Monitoring:
-General: For superinfection (during therapy); treatment response in patients with severe liver dysfunction
-Hepatic: For worsening hepatic function in patients who develop abnormal liver function tests during therapy

Hide
(web1)